Literature DB >> 12230503

Associations of tumor necrosis factor alpha and HLA polymorphisms with adult dermatomyositis: implications for a unique pathogenesis.

Victoria P Werth1, Jeffrey P Callen, Gina Ang, Kathleen E Sullivan.   

Abstract

We recently reported that the -308A tumor necrosis factor alpha promoter polymorphism is associated with the photosensitive disorder subacute cutaneous lupus erythematosus and mediates an exaggerated tumor necrosis factor alpha response to ultraviolet B. We now sought to examine the association of this polymorphism with adult dermatomyositis, a photosensitive disease that exhibits some features in common with subacute cutaneous lupus erythematosus. Fifty adult patients with dermatomyositis and 239 healthy, race-matched controls were examined for the -308A tumor necrosis factor alpha polymorphism and the more common -308G allele. The frequency of the -308A allele was 0.27 in the entire dermatomyositis group, versus 0.14 in the controls (p = 0.003, chi2 2 x 2 table). Caucasians were the only racial/ethnic group in our study large enough to allow separate statistical analysis (47 dermatomyositis, 223 controls). The frequency of the -308A allele was 0.26 for dermatomyositis and 0.14 for controls (p = 0.014). Caucasians are known to exhibit a linkage disequilibrium between -308A and HLA-DR3, which we previously found to be significantly enhanced in subacute cutaneous lupus erythematosus patients. In contrast, we now found no increase in the association of -308A and HLA-DR3 in Caucasians with dermatomyositis compared to controls. Consistent with this observation, the association of these two genes in dermatomyositis was significantly less than we previously reported in Caucasians with subacute cutaneous lupus erythematosus (p = 0.016). We conclude that the tumor necrosis factor -308A polymorphism is associated with dermatomyositis, which suggests a pathophysiologic contribution from ultraviolet-induced production of tumor necrosis factor alpha, similar to subacute cutaneous lupus erythematosus. The differences in linkage with HLA-DR3, as well as several divergent clinical features, indicate that there are also fundamental mechanistic differences between dermatomyositis and subacute cutaneous lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12230503     DOI: 10.1046/j.1523-1747.2002.01869.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  15 in total

Review 1.  Dermatomyositis.

Authors:  M S Krathen; D Fiorentino; V P Werth
Journal:  Curr Dir Autoimmun       Date:  2008

Review 2.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

3.  A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis.

Authors:  Adam Schiffenbauer; Megha Garg; Christine Castro; Angelina Pokrovnichka; Galen Joe; Joseph Shrader; Imelda Victoria Cabalar; Sara Faghihi-Kashani; Michael O Harris-Love; Paul H Plotz; Frederick W Miller; Mark Gourley
Journal:  Semin Arthritis Rheum       Date:  2017-10-16       Impact factor: 5.532

4.  Polymorphisms in the TNF-α and IL10 gene promoters and risk of arsenic-induced skin lesions and other nondermatological health effects.

Authors:  Nilanjana Banerjee; Sujay Nandy; James K Kearns; Apurba K Bandyopadhyay; Jayanta K Das; Papiya Majumder; Santanu Basu; Saptarshi Banerjee; Tanmoy Jyoti Sau; J Christopher States; Ashok K Giri
Journal:  Toxicol Sci       Date:  2011-02-25       Impact factor: 4.849

5.  Successful treatment for conventional treatment-resistant dermatomyositis-associated interstitial lung disease with adalimumab.

Authors:  Jin-Kyoung Park; Han-Gyul Yoo; Dae-Seon Ahn; Hyun-Soon Jeon; Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2011-11-17       Impact factor: 2.631

6.  Dermatomyositis and cutaneous metastases from breast cancer: simultaneous development and parallel course.

Authors:  Mario Vaccaro; Francesco Borgia; Olga Barbuzza; Sebastiano Gangemi; Biagio Guarneri
Journal:  Rheumatol Int       Date:  2009-07-10       Impact factor: 2.631

7.  Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis.

Authors:  Gulnara Mamyrova; Terrance P O'Hanlon; Laura Sillers; Karen Malley; Laura James-Newton; Christina G Parks; Glinda S Cooper; Janardan P Pandey; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Rheum       Date:  2008-12

8.  Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients.

Authors:  P Efthimiou; S Schwartzman; L J Kagen
Journal:  Ann Rheum Dis       Date:  2006-02-13       Impact factor: 19.103

9.  Dermatomyositis masquerading as pulmonary embolism.

Authors:  R M Mroz; M Korniluk; E Chyczewska
Journal:  Eur J Med Res       Date:  2009-12-07       Impact factor: 2.175

Review 10.  Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies.

Authors:  Joerg-Patrick Stübgen
Journal:  J Neurol       Date:  2011-01-21       Impact factor: 6.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.